Diabetes: Difference between revisions

1,249 bytes added ,  21 January 2013
no edit summary
No edit summary
No edit summary
Line 153: Line 153:


===Treatments to reduce cardiovascular risk===  
===Treatments to reduce cardiovascular risk===  
{| class="wikitable" border="0" cellpadding="0" cellspacing="0" width="600px"
|-
!colspan="3"|Treatment to reduce cardiovascular risk <cite>34</cite>
|-
|colspan="3"|'''Lifestyle and comprehensive management'''
|-
!Recommendation
!Class<sup>a</sup>
!Level<sup>b</sup>
|-
|Structured patient education improves metabolic and blood pressure control
!I
!A
|-
|Non-pharmacological life style therapy improves metabolic control
!I
!A
|-
|Self-monitoring improves glycaemic control
!I
!A
|-
|Near normoglycaemic control (HbA1c 6.5%<sup>c</sup>
reduces microvascular complications
reduces macrovascular complications
!I
!A
|-
|Intensified insulin therapy in type 1 diabetes reduces morbidity and mortality
!I
!A
|-
|Early escalation of therapy towards predefined treatment targets improves a composite of morbidity and mortality in type 2 diabetes
!IIa
!B
|-
|Early initiation of insulin should be considered in patients with type 2 diabetes failing glucose target
!IIb
!C
|-
|Metformin is recommended as first line drug in overweight type 2 diabetes
!IIa
!B
|-
|bgcolor="#CCCCFF" colspan="3"|'''<sup>a</sup>Class of recommendation.'''
'''<sup>b</sup>Level of evidence.'''
'''<sup>c</sup>Diabetes Control and Complication Trial-standardized.'''
|}
To reduce the risk of cardiovascular disease, the followings are needed to be considered:  
To reduce the risk of cardiovascular disease, the followings are needed to be considered:  


467

edits